← Back to patent-cliff list
CAS 105-36-2
ethyl 2-bromoacetate
Codes：ELOB-003、DABI-017
Application context (from source-drug indications)
便秘Elobixibat Hydrate非酒精性脂肪性肝炎Elobixibat Hydrate血脂障碍Elobixibat Hydrate静脉血栓栓塞达比加群酯甲磺酸盐栓塞达比加群酯甲磺酸盐中风达比加群酯甲磺酸盐缺血性卒中达比加群酯甲磺酸盐肺栓塞达比加群酯甲磺酸盐静脉血栓形成达比加群酯甲磺酸盐
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Elobixibat HydrateElobixibat Hydrate | Tier C — Watch / trade | - |
| 达比加群酯甲磺酸盐Dabigatran Etexilate Mesylate | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
7-bromo-3,3-dibutyl-8-methoxy-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine 1,1-dioxide→3,3-dibutyl-8-hydroxy-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine 1,1-dioxide→ethyl 2-bromoacetate→ethyl 2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetate→2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetic acid→methyl (R)-2-amino-2-phenylacetate hydrochloride→(R)-tert-butyl 2-(2-(2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetamido)acetate→7-bromo-3,3-dibutyl-8-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine 1,1-dioxide→ethyl 2-((7-bromo-3,3-dibutyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetate→2-((7-bromo-3,3-dibutyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetic acid
(R)-methyl 2-(2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetate→ethyl 2-bromoacetate→(R)-2-(2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetic acid→2-((7-bromo-3,3-dibutyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetic acid→2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetic acid→methyl (R)-2-amino-2-phenylacetate hydrochloride→(R)-tert-butyl 2-(2-(2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetamido)acetate→7-bromo-3,3-dibutyl-8-hydroxy-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine 1,1-dioxide→ethyl 2-((7-bromo-3,3-dibutyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetate→2-((7-bromo-3,3-dibutyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetic acid
ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate→hexyl carbonochloridate→4-aminobenzonitrile→(Z)-4-amino-N'-hydroxybenzimidamide→3-(4-aminophenyl)-1,2,4-oxadiazol-5(4H)-one→ethyl 2-bromoacetate→ethyl (4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)glycinate→(4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)glycine→ethyl 3-(1-methyl-2-(((4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl)amino)methyl)-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate→ethyl 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate
ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate→hexyl carbonochloridate→ethyl 2-bromoacetate→4-nitrobenzonitrile→(Z)-N'-hydroxy-4-nitrobenzimidamide→5-methyl-3-(4-nitrophenyl)-1,2,4-oxadiazole→4-(5-methyl-1,2,4-oxadiazol-3-yl)aniline→ethyl (4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)glycinate→(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)glycine→ethyl 3-(1-methyl-2-(((4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)amino)methyl)-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate→ethyl 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate 4-methylbenzenesulfonate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications |
|---|---|---|---|---|---|
| Qualified Partner — East China API Works | Dabigatran etexilate mesylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | ethyl N-[3-amino-4-(methylamino)benzoyl]-N-pyridin-2-yl-beta-alaninate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | N-(4-cyanophenyl)-Glycine Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.